ArticleLeukemia2014
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06109233 (A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment), which is not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.JAMA oncology · 2017Pooled it
- Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.Blood cancer journal · 2020Trial
- Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.Clinical lymphoma, myeloma & leukemia · 2020Trial
- Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.British journal of haematology · 2015Trial
- Trial
- Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.Blood cancer journal · 2014Trial
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood · 2014Trial
- New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response.Current hematologic malignancy reports · 2026Review
- Characteristics of immunoglobulin gene rearrangements in vietnamese newly diagnosed multiple myeloma patients.Leukemia research reports · 2026Article
- Reduced splenic uptake of [EJNMMI research · 2025Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- MRD in multiple myeloma: the clinical perspective.Frontiers in oncology · 2025Review
- [Minimal residual disease assessment and progress in multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Advances in estimating plasma cells in bone marrow: A comprehensive method review.African journal of laboratory medicine · 2024Review
- Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.Targeted oncology · 2023Article
- Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.Biomedicines · 2023Review
- Review
- Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing.Life science alliance · 2023Article
- Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma.Cancers · 2022Article
- Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.Skeletal radiology · 2022Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for minimal residual disease (MRD) assessment in patients with multiple myeloma (MM), comparing the results with those of multiparameter flow cytometry (MFC). A total of 170 patients enrolled in three consecutive Spanish trials achieving at least partial response after treatment were included. Lack of clonality detection (n=31), unsuccessful sequencing (n=17) and suboptimal ASO performance (n=51) limited the applicability of PCR to 42% of cases. MRD was finally investigated in 103 patients (including 32 previously studied) with persistent disease identified by PCR and MFC in 54% and 46% of cases, respectively. A significant correlation in MRD quantitation by both the techniques was noted (r=0.881, P<0.001), being reflective of treatment intensity. Patients with <10(-4) residual tumor cells showed longer progression-free survival (PFS) compared with the rest (not reached (NR) vs 31 months, P=0.002), with similar results observed with MFC. Among complete responders (n=62), PCR discriminated two risk groups with different PFS (49 vs 26 months, P=0.001) and overall survival (NR vs 60 months, P=0.008). Thus, although less applicable than MFC, ASO RQ-PCR is a powerful technique to assess treatment efficacy and risk stratification in MM.
Indexed as
Identifiers
23860448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.